GlassScriptPhysician profile
Forrest Michael Toca
NPI 1114036076
$6,801.62
in general payments reported to CMS, 2019-2025
28 companies · $805 in 2025
The $805 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $385 · 2021: $1,444 · 2022: $1,222 · 2023: $277 · 2024: $1,840 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,998 · Travel and Lodging: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.58 |
| Travel and Lodging | $923.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,003.68 | 2021-2024 | Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $980.07 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $513.07 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $394.85 | 2019-2024 | Xarelto |
| Abbott Laboratories | $310.15 | 2021-2025 | Jot Dx, Gallant, Assurity |
| Boston Scientific Corporation | $308.00 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Mylux Patient Kit With Mobile Device |
| Merck Sharp & Dohme LLC | $238.55 | 2021-2025 | Verquvo |
| Inspire Medical Systems, INC. | $166.19 | 2024-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.16 | 2019-2020 | |
| Cardiva Medical, INC. | $112.13 | 2021-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Amgen INC. | $109.35 | 2019-2023 | Repatha |
| Kestra Medical Technology Services, INC. | $103.48 | 2024-2025 | Assure Wcd |
| Irhythm Technologies, INC. | $88.55 | 2019-2021 | |
| Philips North America LLC | $42.32 | 2025 | Fleet Management, Extended Holter |
| Vital Connect, INC | $36.60 | 2024-2025 | Vitalpatch Rtm |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $34.82 | 2019 | |
| Alnylam Pharmaceuticals INC. | $28.53 | 2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $27.65 | 2024 | Farxiga |
| Edwards Lifesciences Corporation | $22.72 | 2019-2020 | |
| Cvrx, INC. | $22.47 | 2022 | |
| Biotronik INC. | $21.82 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $19.94 | 2025 | Opsynvi, Uptravi |
| Lexicon Pharmaceuticals, INC. | $18.76 | 2023 | Inpefa |
| Glaxosmithkline, LLC. | $18.25 | 2025 | Benlysta |
| Vivaquant INC, Dba Rhythm Express | $17.00 | 2025 | Rhythm Express |
| E.R. Squibb & Sons, L.L.C. | $13.20 | 2021 | |
| Esperion Therapeutics, INC. | $12.76 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Forrest Toca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.